XORTX Therapeutics stock gains as Nasdaq listing takes center stage

XORTX Therapeutics stock (ISIN US98420X1046) is trading as a pure Nasdaq listing after the biotech completed the voluntary delisting of its shares from the TSX Venture Exchange, concentrating liquidity and investor attention in the United States as of early September 2026.

TSXV delisting shifts focus fully to Nasdaq

According to a company announcement summarized by TipRanks, XORTX Therapeutics received final approval on August 28, 2026 to voluntarily delist its common shares from the TSX Venture Exchange, with the delisting taking effect after the close of business on September 1, 2026.

The same announcement notes that the companys shares continue to trade on the Nasdaq Capital Market under the symbol XRTX, underscoring that the stock is now positioned solely on a major U.S. exchange rather than splitting liquidity between Toronto and New York.

Investor-relations push and revenue expectations

Following completion of the TSXV delisting, XORTX re-engaged its investor-relations agency under a revised consulting agreement signed on September 2, 2026, with services commencing on September 3, 2026, in what TipRanks describes as a campaign valued at about USD 2.5 million and focused on raising visibility among Nasdaq investors.

A Korean financial article on XORTX reports that consensus expectations point to revenue of about USD 3.25 million in 2026 and USD 16.02 million in 2027, implying projected growth of roughly 392 percent year over year between 2026 and 2027, which illustrates how strongly analysts expect the commercialization ramp to accelerate if the company executes its plans.

Small-cap valuation and recent price move

Market data compiled by MarketBeat show XORTX Therapeutics shares at USD 2.31 as of the close reported on September 4, 2026, representing a gain of about 7.44 percent on the day and leaving the company with a market capitalization in the low single-digit million USD range.

The same overview notes that XORTX stock started 2026 at USD 2.81, meaning that despite the recent uptick, the share price is still down approximately 17.8 percent year to date, a reminder that the stock remains volatile and highly sensitive to news flow and investor sentiment typical for pre-revenue or early-revenue biotechnology names.

In pre-market trading highlighted by a Benzinga overview of health-care movers on September 4, 2026, XORTX Therapeutics shares were cited as rising 11.16 percent to USD 2.39 with an indicated market capitalization of about USD 3.9 million, underlining how quickly the stock can react to shifting interest around small biotech names.

Kidney disease pipeline as the business backbone

XORTX Therapeutics focuses on developing therapies for progressive kidney disease, including autosomal dominant polycystic kidney disease and diabetic nephropathy, using formulations designed to reduce serum uric acid and address underlying metabolic drivers of renal decline.

For retail investors, the central business question is whether clinical progress and potential regulatory milestones over the next several years can support the ambitious revenue projections cited for 2026 and 2027, given that the company is still in the early stages of building a commercial footprint.

Stock remains a speculative biotech play

As of September 5, 2026, XORTX Therapeutics stock remains listed exclusively on the Nasdaq Capital Market under ticker XRTX and not on Xetra or other DACH trading venues, making the Nasdaq quote the primary reference for investors monitoring the share price.

With a share price around the low single digits in USD and a market capitalization of only a few million USD, the stock represents a highly speculative exposure within the biotechnology sector, where outcomes are closely tied to clinical trial data, regulatory decisions and the companys ability to convert its pipeline into sustainable revenue.